brinsupri insmed - Search News

News

FDA, Brinsupri

Insmed wins FDA approval for future blockbuster Brinsupri

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (DPP1) inhibitor and the first therapy for non-cystic fibrosis bronchiectasis (NCFB) approved by the US Food and Drug Administration (FDA).

BioPharma Dive · 2d

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis.

PharmExec · 2d

FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.

Fierce Pharma2d

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit ...

Stocktwits on MSN1d

HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Insmed Gets FDA OK of Brinsupri in Non-Cystic Fibrosis Bronchiectasis

Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...

TipRanks on MSN2d

Brinsupri approval sets stage for next leg of Insmed growth, says BofA

After Insmed (INSM) announced the FDA approved brensocatib as “Brinsupri,” making it the first approved treatment for non-cystic fibrosis ...

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Hosted on MSN2d

Insmed price target raised to $138 from $120 at RBC Capital

After Insmed (INSM) announced the FDA approved Brinsupri for non-cystic fibrosis bronchiectasis, RBC Capital raised the firm’s price target on Insmed to $138 from $120 and keeps an Outperform ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results